Hypoxia-induced decoy receptor 2 gene expression is regulated via a hypoxia-inducible factor 1alpha-mediated...

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Signaling

Background:

• Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows promise for anti-cancer therapy due to its cancer cell selectivity.
• TRAIL exerts its effects through death receptors (DR4, DR5) and decoy receptors (DcR1, DcR2).
• Solid tumors often exhibit hypoxia, which can confer resistance to chemotherapy, including TRAIL-based treatments.

Purpose of the Study:

• To investigate the impact of hypoxia on TRAIL receptor expression in human colon cancer cells.
• To elucidate the molecular mechanisms underlying hypoxia-induced changes in TRAIL receptor expression.
• To determine the functional consequences of these changes on TRAIL-mediated apoptosis.

Main Methods:

• Cultured five human colon cancer cell lines under normoxic and hypoxic conditions.
• Analyzed TRAIL receptor protein and gene expression using flow cytometry and RT-PCR.
• Investigated the role of transcription factors (HIF-1α, p53, NF-κB) using genetic and pharmacological approaches.

Main Results:

• Hypoxia significantly upregulated DcR2 protein expression on the cell surface of all tested colon cancer cell lines.
• Hypoxia did not affect DR4, DR5, or DcR1 protein levels; DcR2 upregulation resulted from increased gene transcription.
• Hypoxia-inducible factor 1-alpha was identified as a key regulator of DcR2 transcription, while p53 and NF-κB were not involved.
• TRAIL-induced apoptosis was attenuated under hypoxic conditions, correlating with increased DcR2 levels.

Conclusions:

• Increased DcR2 expression under hypoxia is a significant mechanism contributing to TRAIL resistance in colon cancer.
• Hypoxia-inducible factor 1-alpha plays a critical role in mediating this resistance.
• Targeting DcR2 or modulating hypoxic responses may enhance the efficacy of TRAIL-based cancer therapies.